Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis

Critical Care Medicine

Volumn 38, Issue 6, 2010, Pages 1414-1422

  Van Zoelen, Marieke A D ^a,b   Achouiti, Ahmed ^a   Schmidt, Ann Marie ^c   Yang, Huan ^d   Florquin, Sandrine ^a   Tracey, Kevin J ^d   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Howard Hughes Medical Institute   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

High mobility group; Host defense; Peritonitis; Sepsis; Soluble receptor for advanced glycation end products (sRAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PERITONITIS; BACTERIAL TRANSMISSION; CONTROLLED STUDY; CYTOKINE RELEASE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HISTOPATHOLOGY; HOST RESISTANCE; IMMUNE RESPONSE; IN VIVO STUDY; LIGAND BINDING; LIVER CELL DAMAGE; LIVER PARENCHYMA; LUNG PARENCHYMA; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 77953082550     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de18bc     Document Type: Article

References (50)

1. McClean KL, Sheehan GJ, Harding GK: Intraabdominal infection: A review. Clin Infect Dis 1994; 19:100-116
2. Holzheimer RG, Muhrer KH, L'Allemand N, et al: Intraabdominal infections: Classification, mortality, scoring and pathophysiology. Infection 1991; 19:447-452
3. Schmidt AM, Yan SD, Yan SF, et al: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498:99-111
4. Yan SD, Zhu H, Zhu A, et al: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6:643-651
5. Yan SD, Chen X, Fu J, et al: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382:685-691
6. Moroz OV, Antson AA, Dodson EJ, et al: The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr 2002; 58:407-413
7. Valencia JV, Mone M, Zhang J, et al: Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 2004; 53:743-751
8. Arumugam T, Simeone DM, Schmidt AM, et al: S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004; 279:5059-5065
9. Sorci G, Riuzzi F, Arcuri C, et al: Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol 2004; 24:4880-4894
10. Hori O, Brett J, Slattery T, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-25761
11. Andersson U, Tracey KJ: HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 2004; 30:627-637, xi
12. Czura CJ, Yang H, Amella CA, et al: HMGB1 in the immunology of sepsis (not septic shock) and arthritis. Adv Immunol 2004; 84: 181-200
13. Huttunen HJ, Fages C, Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274:19919-19924
14. Bierhaus A, Schiekofer S, Schwaninger M, et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50:2792-2808
15. Humpert PM, Djuric Z, Kopf S, et al: Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6:9
16. Falcone C, Emanuele E, D'Angelo A, et al: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25:1032-1037 (Pubitemid 40627851)
17. Uchida T, Shirasawa M, Ware LB, et al: Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173:1008-1015
18. Cataldegirmen G, Zeng S, Feirt N, et al: RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005; 201: 473-484
19. Zeng S, Feirt N, Goldstein M, et al: Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004; 39:422-432
20. Ekong U, Zeng S, Dun H, et al: Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 2006; 21:682-688
21. Park L, Raman KG, Lee KJ, et al: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4:1025-1031
22. Goova MT, Li J, Kislinger T, et al: Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159:513-525
23. Liliensiek B, Weigand MA, Bierhaus A, et al: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-1650
24. Hofmann MA, Drury S, Hudson BI, et al: RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3:123-135
25. Yan SS, Wu ZY, Zhang HP, et al: Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003; 9:287-293
26. Pullerits R, Brisslert M, Jonsson IM, et al: Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006; 54:3898-3907
27. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101:296-301
28. Qin S, Wang H, Yuan R, et al: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203:1637-1642
29. Lutterloh EC, Opal SM, Pittman DD, et al: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11:R122
30. Buras JA, Holzmann B, Sitkovsky M: Animal models of sepsis: Setting the stage. Nat Rev Drug Discov 2005; 4:854-865
31. van Westerloo DJ, Giebelen IA, Florquin S, et al: The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 2005; 191: 2138-2148
32. Renckens R, Roelofs JJ, Florquin S, et al: Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in Mice. J Immunol 2006; 177:1189-1196
33. Renckens R, Roelofs JJ, Florquin S, et al: Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 2006; 176:3735-3741
34. Renckens R, Roelofs JJ, ter Horst SA, et al: Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175: 6764-6771
35. Hofmann MA, Drury S, Fu C, et al: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901
36. Kalea AZ, Reiniger N, Yang H, et al: Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 2009; 23:1766-1774
37. van Zoelen MA, van der Sluijs KF, Achouiti A, et al: Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009; 391: 265-273
38. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
39. Leemans JC, Vervoordeldonk MJ, Florquin S, et al: Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med 2002; 165:1445-1450
40. Rijneveld AW, Weijer S, Florquin S, et al: Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103: 1702-1709
41. Knapp S, Leemans JC, Florquin S, et al: Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003; 167:171-179
42. Weijer S, Schoenmakers SH, Florquin S, et al: Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J Infect Dis 2004; 189:2308-2317
43. Rijneveld AW, Levi M, Florquin S, et al: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168:3507-3511
44. Walley KR, Lukacs NW, Standiford TJ, et al: Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect Immun 1997; 65:3847-3851
45. Olson TS, Ley K: Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002; 283:R7-R28
46. Sewnath ME, Olszyna DP, Birjmohun R, et al: IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001; 166:6323-6331
47. Degryse B, de Virgilio M: The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett 2003; 553:11-17
48. van Zoelen MA, Yang H, Florquin S, et al: Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009; 31: 280-284
49. Tsung A, Sahai R, Tanaka H, et al: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201:1135-1143
50. Zetterstrom CK, Bergman T, Rynnel-Dagoo B, et al: High mobility group box chromosomal protein 1 (HMGB1) is an antibacterial factor produced by the human adenoid. Pediatr Res 2002; 52:148-154